Jamming a protein signal forces cancer cells to devour themselves
Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research
MD Anderson News Release 04/03/14
Under stress from chemotherapy or radiation, some cancer cells dodge death by consuming a bit of themselves, allowing them to essentially sleep through treatment and later awaken as tougher, resistant disease.
Interfering with a single cancer-promoting protein and its receptor can turn this resistance mechanism into lethal, runaway self-cannibalization, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cell Reports.
“Prolactin is a potent growth factor for many types of cancers, including ovarian cancer,” said senior author Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine. “When we block prolactin signaling, it sets off a chain of downstream events that result in cell death by autophagy.”
Autophagy – self-eating – is a natural cellular defense against lack of nutrients and other stressors. It also recycles damaged organelles and proteins for new use by the cell. Autophagy puts the cell in an inactive quiet state called quiescence, which allows it to recover, Sood said. For cancer cells, it’s a way to survive treatment.
“Our findings provide a clinical rationale for blocking prolactin and its receptor and for using prolonged autophagy as an alternative strategy for treating cancers,” said Yunfei Wen, Ph.D., first author of this study and instructor of Gynecologic Oncology.
Steep reductions in tumor weight for mice with ovarian cancer
Prolactin (PRL) is a hormone previously implicated in ovarian, endometrial and other cancer development and progression. When PRL binds to its cell membrane receptor, PRLR, activation of cancer-promoting cell signaling pathways follows. Poor understanding of the underlying processes has made the pathway hard to target for cancer treatment, Sood said.
Given that knowledge, the researchers started with mouse experiments and worked backward to cell line experiments, a reversal of the usual order of preclinical cancer research.
A slight variant of normal prolactin called G129R interferes with the connection between prolactin and its receptor. Using G129R, Sood and colleagues treated mice that had two different lines of human ovarian cancer that each expresses the prolactin receptor.
After 28 days of treatment with G129R, tumor weights fell by 50 percent for mice with either type of ovarian cancer. Adding the taxane-based chemotherapy agent paclitaxel, commonly used to treat ovarian cancer, cut tumor weight by 90 percent. Higher doses of G129R may result in even greater therapeutic benefit, Sood said.
The mice did not otherwise lose weight, suffer lowered blood counts or show any other sign of toxicity of side effects from G129R treatment in the liver, spleen or kidneys.
3D experiments show death by self-eating
The team used three-dimensional culture of cancer spheroids, where treatment with the prolactin-mimicking peptide sharply reduced the number of spheroids. Treatment also blocked the activation of JAK2 and STAT signaling pathways known to promote cancer.
Protein analysis in the treated spheroids showed increased presence of autophagy factors and genomic analysis revealed increased expression of a number of genes involved in autophagy progression and cell death.
A series of experiments using fluorescence and electron microscopy showed that the cytosol of treated cells had large numbers of cavities caused by autophagy, a hallmark of autophagy-induced cell death.
Autophagy works by encasing targeted proteins or organelles in a membrane, which then connects with lysosomes that dissolve the contents, leaving empty cavities, or vacuoles. Adding an autophagy inhibitor reversed the treatment effect of G129R in the 3D spheres.
Connection to ovarian cancer patient survival
The team also connected the G129R-induced autophagy to the activity of PEA-15, a known cancer inhibitor. Analysis of tumor samples from 32 ovarian cancer patients showed that tumors express higher levels of the prolactin receptor and lower levels of phosphorylated PEA-15 than normal ovarian tissue.
Patients with low levels of the prolactin receptor and higher PEA-15 had longer overall survival than those with high PRLR and low PEA-15.
The researchers are working to take G129R to clinical trials said Sood, who holds the Bettyann Asche Murray Distinguished Professorship in Ovarian Cancer Research.
Co-authors with Wen and Sood are Behrouz Zand, M.D., Chunhua Lu, M.D., Ph.D., Amy Carroll, M.D., Yu Kang, M.D., Ph.D., Rajesha Rupaimoole, Heather Dalton, M.D., and Robert Coleman, M.D., of Gynecologic Oncology and Reproductive Medicine; Bulent Ozpolat, M.D., Ph.D., Erkan Yuca, Ph.D., Neslihan Alpay, Ph.D., Ibrahim Tekedereli, M.D., Walter Hittelman, Ph.D., and Gabriel Lopez-Berestein, M.D., of Experimental Therapeutics; Chandra Bartholomeusz Ph.D., M.D., and Naoto Ueno, M.D., Ph.D., of Breast Medical Oncology; Chad Pecot, M.D., of Thoracic, Head and Neck Oncology; Jinsong Liu, M.D., Ph.D., of Pathology; Anadulce Hernandez, Biology and Biochemistry, University of Houston; Miroslaw J. Szczepanski, M.D., Ph.D., of the Medical University of Warsaw, Poland; Marta Szajnik, M.D., Ph.D., of Poznan University of Medical Sciences, Poznan, Poland; Anna Lokshin, Ph.D., Hillman Cancer Center, University of Pittsburgh Cancer Institute; Susan Lutgendorf, Ph.D., Psychology and Obstetrics and Gynecology, University of Iowa; Wen Chen, Ph.D., Biological Sciences, Clemson University.
Sood, Coleman, Ozpolat and Lopez-Berestein are associated with the Center for RNA Interference and Non-Coding RNA at MD Anderson. Rupaimoole is a graduate student in The University of Texas Graduate School of Biomedical Sciences at Houston, a joint program of MD Anderson and The University of Texas Health Science Center at Houston.
Portions of this work were supported by grants from the National Cancer Institute of the U.S. National Institutes of Health (P50CA083639, P50CA098258, CA109298, RC2GM092599, U54 CA151668, CA140933, and CA16672), the U.S. Department of Defense, the Ovarian Cancer Research Fund, the Chapman Foundation, the Meyer and Ida Gordon Foundation, and the Blanton-Davis Ovarian Cancer Research Program.